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Highlights 
∗ Control of HIV with cART fails to reduce the incidence of many lymphomas. 
∗ Replication of HIV in lymph nodes may affect lymphoma risk during therapy. 
∗ Replication of HIV in adipose tissue may create a lymphoma-promoting 
metabolic state. 
∗ HIV pathology in reservoirs may inform mechanisms of cART-resistant 
lymphoma risk.  
 
Abstract  
Non-Hodgkin lymphomas are highly increased in incidence in individuals infected with HIV, 
and this continues to be the case in spite of highly effective combined antiretroviral therapy 
(cART). New evidence has demonstrated that while successful virtual recovery of CD4 
counts and elimination of HIV from peripheral blood can be achieved with cART, viral 
replication can still occur in lymphoid tissues. In addition, recent studies have suggested 
that adipose tissue provides an additional reservoir for HIV-infected macrophages and T 
lymphocytes even in the context of successful cART therapy. In this review article, we 
discuss possible mechanisms leading to the development of lymphoma in the cART era. 
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Introduction 
The incidence of Kaposi Sarcoma (KS) and other AIDS-defining cancers has decreased 
significantly since combined antiretroviral therapy (cART) became widely available [1], but 
overall cancer incidence is increasing in patients living with HIV (PLWH) [2]. Indeed, the 
D:A:D study recently concluded that malignancy is now the leading cause of non-AIDS-
related mortality in the PLWH [3]. Although some studies attribute this trend to increased 
survival rates in the cART era producing an aging HIV-infected population [4], 
standardized incidence ratios for several cancers including anal, liver, and lung 
malignancies are demonstrably higher in the HIV-positive population compared to the 
general population [5]. Importantly, the incidence of malignancy in this cohort can be 
correlated with lower CD4+ T cell count at cART initiation [5], suggesting that HIV-
mediated immunosuppression predisposes patients to malignancy even when HIV disease 
is later controlled. Malignant lymphoproliferation is common in HIV positive patients 
regardless of treatment status [6], and non-Hodgkin lymphomas (NHL) are still considered 
an AIDS-defining cancer. Although incidence of some types of NHL have decreased in the 
cART era, other manifestations of NHL are increasing and NHL remains a significant 
source of mortality in HIV-infected individuals [7,8]. In fact, lymphomas have become the 
most common AIDS-related cancer in the developed world, constituting over 50% of all 
AIDS defining cancers and the most common cause of cancer-related death in HIV-
infected individuals [9]. Interestingly, KSHV co-infection further increases the risk of NHL 
in HIV positive patients  [10], and rates of KSHV-associated PEL and MCD remain rare but 
are unaffected by the widespread use of cART [5,11]. Similarly, incidence of EBV-
associated lymphomas including Burkitt lymphoma and classical Hodgkin’s Lymphoma 
(cHL) remains high. Moreover, aggresive histological subtypes of cHL occur more 
frequently in PLWH and these cases are often characterized by increased numbers of 
pathogenic Reed-Sternberg cells that are EBV infected, suggesting that EBV has an 
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unusual role in cHL pathogenesis in the context of HIV infection [6,12]. Taken together, 
these data suggest that (1) HIV infection predisposes patients to malignant 
lymphoproliferation in general and (2) cART-mediated immune reconstitution is not always 
sufficient to prevent disease progression in PLWH. In this review, we will highlight some of 
the recent reports which may shed light on the persistence of lymphoma in PLWH in the 
context of successful cART treatment. 
Persistent replication of HIV in lymph node reservoirs 
Despite the success of cART at preventing the progression of HIV infection to AIDS, it is 
now apparent that more subtle HIV-mediated pathology, including increased susceptibility 
to malignancy, persists even in well-controlled patients with high CD4 counts and 
undetectable levels of circulating HIV. The concept that latent reservoirs of HIV infected 
cells persist in anatomical sites where penetration of cART drugs is low has received 
considerable attention in recent years as a significant barrier to achieving an HIV cure 
[13,14]. Indeed, viral persistence in lymph nodes and gut-associated lymphoid tissues 
(GALT) under cART therapy has been documented in both HIV [15] and SIV [16,17] 
infection. However, the definition of these reservoirs as “latent” has recently been 
challenged in an elegant study by Lorenzo-Redondo et al, which demonstrates that HIV 
continues to replicate in lymphoid tissue and traffics between the lymph nodes and blood 
even in the context of effective cART-mediated suppression of plasma viremia. Moreover, 
the authors posit that viral evolution in these protected niches may be independent of 
selective pressure from cART therapy [18]. This provides us with a theoretical context in 
which the persistent immune dysfunction found in PLWH successfully treated with cART 
may be due to residual viral pathogenesis restricted to the lymph nodes rather than 
aberrations caused by dysregulated immune reconstitution. Indeed, recent evidence 
suggests that germinal center resident follicular helper T lymphocytes (Tfh) may be a site 
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of HIV persistence [17,19,20] and that the lack of CD8+ T cell surveillance of the germinal 
center [21] may contribute to the escape of HIV-infected T cells from elimination by CTL in 
this niche. Moreover, these results create a framework in which we can hypothesize HIV-
infected T lymphocytes in germinal centers contribute to the development of lymphoma in 
PLWH and that this pathology persists during cART. 
Contribution of HIV to a lymphomagenic microenvironment during cART 
Given the novel finding that HIV continues to replicate in lymph nodes during cART 
therapy, and that germinal center-resident Tfh cells are a particularly critical cell type for 
HIV persistence, we will now consider possible mechanisms, other than the obvious 
possibility of chronic antigenic stimulation, by which HIV might contribute to lymphoma risk 
in this context. 
Effects of follicular T cell subsets in the germinal center 
Recent findings suggest that Tfh from HIV-infected individuals are phenotypically [20] and 
functionally [22] distinct from those of uninfected controls, raising the possibility that the 
significant aberrations in B cell development and function observed during chronic HIV 
infection [23,24] might stem from effects of HIV-infected Tfh on the germinal center 
reaction. Appropriate Tfh function is also critical to the control of chronic viral infection 
[25,26], suggesting that HIV-mediated dysfunction in this cell type may also play a role in 
lymphoma pathogenesis driven by viral co-pathogens such as EBV and KSHV. 
Interestingly, Cubas et al demonstrated that Tfh from HIV-infected subjects displayed 
increased IL-21 production after ex vivo stimulation [22]. Given the well-documented 
effects of IL-21 on EBV latency and LMP1 expression [27-29], it is interesting to speculate 
that HIV-driven changes in Tfh function might enhance B cell transformation by EBV. 
Similarly, it was recently shown that expanded Tfh cell populations in individuals 
chronically infected with HIV are associated with an increase in germinal center B cells 
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and plasma cells, decrease of memory B cells and IgG1 hypersecretion [30]. Moreover, 
the expansion of T follicular regulatory cells (Tfr) in HIV disease adds a layer of complexity 
to this milieu [31]. Taken together, the expansion of both Tfh and Tfr would have the 
expected outcome of diminishing B cell activation. Instead, these expansions are 
coincident with excessive B lymphocyte activation [32] and hypergammaglobulinemia [33], 
underscoring the fact that, although follicular T lymphocyte subsets increase in frequency, 
their normal lymph node functions are perturbed in the context of chronic HIV infection 
leading to poorly-understood alterations in B cell physiology (Figure 1). Certainly, 
additional mechanisms underlying lymphoma development in this context will continue to 
evolve along with our understanding of the normal and pathological role of follicular T cell 
subsets in the germinal center reaction. 
 Chronic B cell stimulation 
It is well known that HIV-induces chronic B cell stimulation, which may be critical for the 
development of lymphoma [32,34,35]. In particular germinal center expansion, as seen as 
a florid follicular hyperplasia at the early stages of AIDS, is thought to contribute to 
lymphomagenesis. This is the site where B cell receptor rearrangements occur (i.e class 
switching) and also somatic hypermutation through the effects of activation-induced 
cytidine deaminase (AID), and these events can result in mistakes involving oncogenic 
genetic alterations. In addition, lymphomas in HIV-infected patients are most frequently of 
germinal center cell origin (including Burkitt lymphoma and GC-subtype of diffuse large B 
cell lymphoma). These B cell abnormalities were still present in cART-treated patients, 
albeit somewhat diminished when compared to untreated patients. This indicates that 
even in the context of good peripheral HIV control through cART, there are B cell 
abnormalities that could play a role in lymphoma development. 
Direct effects of HIV virions and proteins on lymphomagenesis 
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If HIV maintains active replication in lymph nodes during cART treatment, we must 
consider that direct functions of HIV virions and/or HIV proteins on B cell functionality may 
also persist even if HIV does not directly infect the B cells that give rise to lymphomas. A 
number of potential mechanisms by which HIV proteins might directly contribute to 
lymphoma have previously been characterized [1,36], and specifically a number of these 
may contribute to B cell hyperplasia, including Tat [37], Nef [38,39], Env gp120 [40], Env 
gp130 and Gag p17 [41]. Tat has inhibitory effects on DNA repair mechanisms in B cells 
[42], and can activate DNMT1 resulting in aberrant hypermethylation of target genes [43]. 
HIV viral proteins have been shown to interact with other oncogenic herpesviral proteins, 
even if expressed in different cells, through secretion or transmission of HIV proteins by 
structures like nanotubules or exosomes (reviewed in [44,45]). Two studies have 
documented interactions between HIV Nef and KSHV: (1) Nef could synergize with KSHV 
vIL-6 and activate the AKT pathway, which lead to angiogenesis and tumor formation in a 
model of Kaposi sarcoma [46] and (2) Nef was shown to regulate KSHV latency by 
inducing cellular miRNA 1258 (hsa-miR-1258) that directly targets a seed sequence in the 
3' untranslated region of the mRNA encoding the major lytic switch protein of KSHV (RTA) 
[47]. HIV Nef was shown to be secreted in exosomes [48] and to penetrate bystander, 
uninfected B cells [38]. Thus, it may have an effect in maintaining latency of EBV or 
KSHV-infected B cells that eventually become transformed. Transgenic mice expressing 
the HIV protein Tat develop B cell lymphoma, a phenotype that might be linked to the 
ability of Tat to induce production of IL-6 and IL-10. Using another transgenic mouse 
model, Curreli et. al. recently described the association of pre-lymphoma 
lymphadenopathy associated with increased expression of the HIV proteins p17 and 
gp120 [49]. Indeed, high levels of p17 persist in lymph nodes of PLWH, even under the 
influence of cART [50,51]. Working from these observations, Dolcetti and colleagues 
recently demonstrated that particular p17 sequence variants are expressed in HIV patients 
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presenting with NHL, and that these altered p17 proteins have direct effects on B cell 
proliferation and signaling to Akt and PTEN [52]. It is particularly interesting to consider 
that these lymphomagenic p17 variants may arise during HIV sequence evolution in lymph 
nodes during cART, thus providing a source of lymphoma risk independent of treatment 
status. A different mechanism by which HIV itself may affect lymphoma development is 
suggested by the observation that host-derived CD40L can be incorporated into virions 
and the binding of these virions to B lymphocytes can potentiate activation and 
proliferation mimicking the endogenous CD40-CD40L interaction [40]. 
Adipose tissue reservoirs and implications for lymphoma 
An increasing number of population studies are linking both infection and cART treatment 
with increased incidence of obesity in PLWH [53,54]. Although there is no consensus in 
the clinical literature as to whether there is a direct association between obesity and risk of 
NHL in the general population [55], recent studies suggest that in the context of HIV 
infection in general, and PLWH on cART specifically, obesity coupled with specific defects 
in adipose tissue metabolism could provide a context in which lymphoma risk is increased. 
In particular, recent studies demonstrate that adipose tissue provides an additional 
reservoir for HIV-infected immune cells (macrophages and T lymphocytes) even in the 
context of successful cART therapy [56,57], and studies using SIV infection of non-human 
primates (NHP) conclusively demonstrate that HIV infection of adipose tissue contributes 
to metabolic abnormalities and systemic inflammation during chronic infection [56,58], 
similar to what is observed in PLWH. Moreover, a significant proportion of PLWH on cART 
therapy have lipodystrophy, characterized by a loss of subcutaneous adipose tissue 
coupled with an increase in visceral adipose tissue [59-61] and these modifications are 
associated with chronic inflammation and, specifically, increased levels of serum leptin 
and IL-6 [62]. Increased expression and circulation of leptin was also reported in chronic 
SIV infection in NHP [58]. Aside from the obvious contribution of chronic inflammation in 
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lipodystrophy to lymphoma risk, a number of recent studies specifically link leptin signaling 
to pathogenesis in lymphoma via induction of PI3K/Akt signaling [63-66]. Thus, it seems 
that adipose-specific metabolic defects in PLWH undergoing cART treatment could directly 
contribute to lymphoma risk via increases in circulating leptin. Moreover, a number of 
direct effects of HIV accessory proteins on adipocyte functions have been described in 
animal models [67,68] and human cells [69-71] many of which could contribute to the 
induction of a lymphoma-promoting chronic inflammatory state. 
Conclusions 
A great deal of progress has been made controlling HIV infection and preventing the 
progress to full-blown AIDS. This has led to a marked decrease of some AIDS defining 
malignancies like Kaposi sarcoma, but surprisingly not their disappearance and some 
cancers may even be rising in incidence as people with HIV infection are living longer. Of 
note, lymphomas are occurring in people with controlled HIV infection and no obvert 
immunodeficiency. While lymphoma is considered an “AIDS defining condition”, these 
individuals may not have other evidence of AIDS, such as opportunistic infections, and 
respond to lymphoma treatment with survival comparable to that of HIV-negative 
individuals.  Thus, one could argue that lymphoma should no longer be considered an 
“AIDS-defining cancer”, but rather an “HIV-associated malignancy”. 
HIV is considered an oncogenic pathogen, although it does not directly infect the cancer 
cells [1], and an indirect role related to inflammation and HIV proteins that may be 
secreted has been implicated for some time. However, control of HIV should have 
eliminated these factors responsible for lymphoma development. A possible explanation 
has been that HIV infection results in upregulation of AID, which induces gene 
rearrangements and somatic hypermutation in B cells and could induce aberrant genetic 
alterations resulting in permanent damage that leads to lymphoma down the road, 
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regardless of subsequent control of HIV. However, this phenomenon has not been 
formally demonstrated experimentally. The recent evidence demonstrating that HIV 
continues to replicate in lymph node reservoirs even in the context of successful cART 
suppression of plasma viremia creates a new scenario wherein the effects of HIV on 
follicular T cell subsets as well as direct effects of HIV proteins may induce lymphoma 
development, even in when HIV disease is well-controlled, and may explain the continued 
prevalence of HIV-associated lymphomas in the era of effective antiretroviral therapy.  
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Figure Legend 
Figure 1: Model of intra-follicular dysfunction leading to lymphoma in chronic HIV infection.  
(A) In normal lymph nodes, Tfr regulate the proliferation and function of Tfh, which, in turn, 
suppress replication of lymphotrophic pathogens KSHV and EBV and regulate the 
germinal center reaction and production of memory B lymphocytes and plasma cells. (B) 
HIV infection results in expansion of both Tfr and Tfh subsets, but dysregulates their 
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interaction as well as the ability of Tfh to provide appropriate help to B cells, creating a 
decrease in memory B cell production and dysregulation of plasma cell differentiation.  
Suppression of Tfh function could allow proliferation of lymphotrophic pathogens KSHV 
and EBV and allow direct lymphomagenesis by viral mechanisms.  Additionally, HIV gene 
products and virions accumulating in lymph nodes contribute directly to both B cell 
dysfunction and viral lymphomagenesis. 
 

